Two Years After Category A: The VHP Adoption Landscape in 2026

Two years have passed since the FDA formally reclassified vaporized hydrogen peroxide sterilization to Category A. The regulatory milestone that many anticipated as a gradual shift has instead accelerated a structural transition in how medical device companies approach sterilization.

The Regulatory Foundation Has Solidified — On Both Sides of the Atlantic

The January 2024 reclassification established VHP as a peer to steam, EtO, and irradiation in FDA submissions. In the two years since, ISO 22441 has matured from a newly published standard into an actively referenced framework in 510(k) and PMA submissions. The validation pathway is no longer theoretical — it is being executed by device manufacturers across multiple product categories.

The impact extends beyond the United States. In the European Union, ISO 22441 provides Notified Bodies with a harmonized standard for assessing VHP sterilization under MDR 2017/745 — giving VHP the same standards-based pathway that EtO manufacturers have long used through ISO 11135. For manufacturers selling into both U.S. and EU markets, a single ISO 22441-aligned validation now supports regulatory submissions in both jurisdictions. Health Canada, TGA (Australia), and regulatory authorities across Asia-Pacific similarly reference ISO standards, extending the reach further.

Simultaneously, EPA ethylene oxide emission reduction mandates have moved from policy to enforcement. Commercial sterilization facilities are investing in abatement technology, raising per-unit costs for contract sterilization. For device manufacturers with sufficient volume, the economic calculus increasingly favors in-house capability over contract dependency.

The Adoption Pattern

The first wave of VHP adoption has followed a predictable pattern. Early movers were device manufacturers with three characteristics: material sensitivity that precluded irradiation, sufficient annual volume to justify capital investment, and engineering teams with the bandwidth to manage a sterilization transition.

These manufacturers are not experimenting with VHP. They are deploying validated systems with IQ/OQ/PQ documentation, biological indicator programs, and ISO 22441-aligned validation protocols. The transition from "evaluating alternatives" to "commissioning systems" has been faster than most industry observers predicted.

What Has Changed for Manufacturers

The practical impact of Category A recognition has materialized in three specific ways:

1. **Regulatory conversations are shorter.** FDA reviewers no longer require extensive justification for VHP as a method. The discussion has shifted from "why VHP?" to "show us your process validation" — the same standard applied to every established sterilization modality.

1. **Contract sterilization costs are rising.** EPA compliance investments at EtO facilities are being passed through to customers. The cost differential between contract sterilization and in-house VHP capability is narrowing, and in some volume scenarios, has already inverted.

1. **Supply chain risk is quantifiable.** Device manufacturers dependent on a single contract sterilizer have experienced the vulnerability of that model. In-house capability eliminates a critical single point of failure in the product release chain.

The PuroGen Perspective

PuroGen has been operating VHP sterilization under FDA regulation since 2003 — over two decades before Category A recognition. The reclassification did not change our methodology; it confirmed it. What has changed is the volume of manufacturers seeking custom VHP systems designed for their specific device portfolios.

The pattern we see: device manufacturers arrive having already decided to transition. What they need is not persuasion — it is engineering. A system configured for their materials, validated against their regulatory requirements, and commissioned in their facility. That is the work we do.

Looking Forward

The convergence of regulatory clarity, economic pressure, and supply chain logic suggests the second wave of VHP adoption will be larger and faster than the first. Manufacturers who began evaluation in 2024 are now commissioning systems. Those beginning now will benefit from the validation precedents and engineering refinements established by early adopters.

Without validated sterilization, no downstream packaging, labeling, or release step can proceed. The sterilization step governs the entire product release chain. Manufacturers who control that step control their timeline.